All In MedTech

Device Trial Radar · NCT04905693

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

An Open-label Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease (TETON-OLE)

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

1,850

Planned (sponsor's estimate)

Start

Sep 6, 2022

Primary completion

Dec 2029

Study completion Dec 2029

Sponsor

Lead sponsor
United TherapeuticsNot on our public-company list
Sponsor type
Industry
First posted
May 28, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.

Conditions

  • Idiopathic Pulmonary Fibrosis
  • Interstitial Lung Disease
  • Progressive Pulmonary Fibrosis

Interventions

  • Inhaled TreprostinilDrug

    Inhaled Treprostinil (6 mcg/breath) administered QID

  • Treprostinil Ultrasonic NebulizerDevice

    Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Long-term safety and tolerability of inhaled treprostinil in subjects with IPF or PPFTime frame: Baseline to 6 years

Locations

192 sites in 18 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama

  • Clinical Trials Center of Middle Tennessee

    Franklin, Arizona

  • Banner University Medical Center-Phoenix

    Phoenix, Arizona

189 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.